CNAT Conatus Pharmaceuticals Inc.

1.98
-0.06  -3%
Previous Close 2.04
Open 2.05
Price To Book 3.97
Market Cap 65777713
Shares 33,144,066
Volume 304,206
Short Ratio
Av. Daily Volume 914,896

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 19576517
  2. 8-K - Current report 181218888
  3. 8-K - Current report 181218887
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181154859
  5. 8-K - Current report 181153705

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b completion of enrolment announced February 12, 2019 with data due mid-2019.
Emricasan
NASH cirrhosis - ENCORE-LF trial
Phase 2b data released December 5, 2018 did not meet primary endpoint. 48-week liver function data due mid-2019.
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2 topline data released Jan 2015
Emricasan
Acute-on-Chronic Liver Failure (ACLF)
Phase 2b data released April 4, 2018. Primary endpoint not met.
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2 data are due 1H 2019.
Emricasan
NASH fibrosis - ENCORE-NF trial
Phase 2 topline data released early January 2016
Emricasan
Liver Cirrhosis
Phase 2 data released September 2015.
Emricasan
Portal Hypertension

Latest News

  1. Conatus (CNAT) Completes Enrollment in Phase II NASH Study
  2. Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
  3. Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals
  4. Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?
  5. Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials
  6. Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
  7. The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
  8. Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
  9. The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
  10. Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
  11. Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint
  12. Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis
  13. Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
  14. When Will Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Become Profitable?
  15. Do Options Traders Know Something About Conatus (CNAT) Stock We Don't?
  16. Edited Transcript of CNAT earnings conference call or presentation 1-Nov-18 8:30pm GMT
  17. Today’s Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Titan Pharmaceuticals

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 19576517
  2. 8-K - Current report 181218888
  3. 8-K - Current report 181218887
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181154859
  5. 8-K - Current report 181153705
  6. 8-K - Current report 181069022
  7. 424B5 - Prospectus [Rule 424(b)(5)] 18988568
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988327
  9. 8-K - Current report 18984758
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 18945942